Perrigo Company plc Other Non-Current Liabilities
Perrigo Company plc (PRGO) had Other Non-Current Liabilities of $608.80 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-05
- 2026-06-27: Other Liabilities, Noncurrent $608.80M.
- 2026-03-28: Other Liabilities, Noncurrent $712.30M.
- 2025-12-31: Other Liabilities, Noncurrent $814.30M.
- 2025-09-27: Other Liabilities, Noncurrent $689.70M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-27 | $608.80M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $712.30M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $814.30M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $689.70M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $673.40M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $541.50M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $499.20M 10-K · filed 2026-02-26 | |
| 2024-09-28 | $660.30M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $535.40M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $526.20M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $559.80M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $613.90M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $658.70M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $637.60M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $623.00M 10-K · filed 2024-02-27 | |
| 2022-10-01 | $573.20M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $577.00M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $554.20M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $530.10M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $565.80M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $554.00M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $533.30M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $539.20M 10-K · filed 2022-03-01 | $643.70M 10-K · filed 2021-03-01 |
| 2020-09-26 | $562.20M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $530.10M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $509.60M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $515.10M 10-K · filed 2021-03-01 | |
| 2019-09-28 | $551.20M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $546.90M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $554.50M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $443.40M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $423.70M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $414.60M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $428.90M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $429.50M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $434.90M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $445.00M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $458.60M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $461.80M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $456.70M 10-Q/A · filed 2017-05-23 | $448.90M 10-Q · filed 2016-11-10 |
| 2016-07-02 | $422.50M 10-Q/A · filed 2017-05-22 | $414.70M 10-Q · filed 2016-08-10 |
| 2016-04-02 | $408.50M 10-Q/A · filed 2017-05-22 | $400.60M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $346.30M 10-K · filed 2018-03-01 | $332.40M 10-KT · filed 2016-02-25 |
| 2015-09-26 | $374.90M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $382.70M 10-K · filed 2017-05-22 | $372.10M 10-K · filed 2015-08-13 |
| 2015-03-28 | $300.50M 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $291.10M 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $286.90M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $293.40M 10-K · filed 2017-05-22 | |
| 2014-03-29 | $275.10M 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $244.50M 10-Q · filed 2014-02-06 | |
| 2013-06-29 | $213.20M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |